Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline

Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points Strengthens balance sheet with cash, cash equivalents and short-term investments of $310 million and extends cash runway into 2027 CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expressi ...